VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

BOPA 2017 | An audit of infusion-related reactions with biosimilar rituximab in London

An important question regarding the use of biosimilar rituximab is whether rapid infusion rates are safe, as they are for the original. Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Simon Cheesman, BPharm, MRPharmS from University College London Hospital (UCLH), London, UK discusses an audit that his center performed for infusion-related reactions with biosimilar rituximab in order to address this concern, with encouraging results. The full results of this audit will be presented as a poster at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, GA. This content has been supported by Napp Pharmaceuticals through an unrestricted educational grant to Magdalen Medical Publishing. The company has had no influence on the production of the content.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter